Renaissance Technologies LLC Trims Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Renaissance Technologies LLC reduced its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 4.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,079,400 shares of the company’s stock after selling 139,400 shares during the period. Renaissance Technologies LLC owned 0.10% of Takeda Pharmaceutical worth $40,771,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Summit Global Investments raised its stake in Takeda Pharmaceutical by 75.5% during the 4th quarter. Summit Global Investments now owns 729,200 shares of the company’s stock worth $9,655,000 after acquiring an additional 313,642 shares during the period. Stifel Financial Corp increased its stake in shares of Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Takeda Pharmaceutical by 284.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $1,447,000. Finally, HighTower Advisors LLC boosted its holdings in Takeda Pharmaceutical by 199.5% in the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after buying an additional 81,653 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 3.3 %

Shares of TAK opened at $13.87 on Friday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.37. The company has a 50 day simple moving average of $14.45 and a two-hundred day simple moving average of $13.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a market cap of $44.12 billion, a P/E ratio of 34.66, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.